NPI 1275567695: Open Payments
NPI 1275567695. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,042 in 17 payments from 7 companies in 2025. Trend: 2023 $1,142 · 2024 $1,224 · 2025 $1,042
Food & beverage: $1,042
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $341 |
| Xeris Pharmaceuticals, Inc. | 3 | $262 |
| Optinose US, Inc. | 1 | $124 |
| Novo Nordisk Inc | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Amgen Inc. | 2 | $39 |
Products named: FARXIGA, BREZTRI, GVOKE HYPOPEN, RECORLEV, Xhance, Ozempic, AUSTEDO XR, CAPLYTA.
